SANTA CLARA, Calif.--DiaDexus, a new company here formed as a joint venture between SmithKline Beecham and Incyte Pharmaceuticals and dedicated to the discovery and commericalization of novel molecular diagnostic products, announced the appointment of William Gerber to the post of president and CEO. Gerber joined DiaDexus from Onyx Pharmaceuticals where he was vice-president and chief operating officer. Previous to that, Gerber was president of Chiron Diagnostics, held various positions with Cetus, and was a practicing physician.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.